title: The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment.
abstract: Ankylosing spondylitis (AS), the most common form of spondyloarthropathy, is a chronic, progressive multi-system inflammatory disorder characteristically affecting the sacroiliac joints and axial skeleton. Although the exact mechanisms underlying the pathogenesis of AS remain to be elucidated, the presence of human leucocyte antigen (HLA)-B27 is known to markedly increase its risk of development. Current treatments include non-steroidal anti-inflammatory drugs (NSAIDs) and tumour necrosis factor (TNF) blockers. In recent years, the interleukin (IL)-23/IL-17 pathway has been shown to have significance in the pathogenesis of AS and treatment modalities targeting this pathway have been shown to be beneficial in various other inflammatory conditions. This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.
authors.affiliation: Oxford University Hospitals NHS Trust, Oxford, UK.
authors.forename: H
authors.initials: H
authors.lastname: Jethwa
authors.affiliation: Oxford University Hospitals NHS Trust, Oxford, UK.|Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, Oxford OX3 7LD, UK.
authors.forename: P
authors.initials: P
authors.lastname: Bowness
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015796:HLA-B27 Antigen / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D020381:Interleukin-17 / Q000378:metabolism*; D053759:Interleukin-23 / Q000378:metabolism*; D058990:Molecular Targeted Therapy; D015398:Signal Transduction; D013167:Spondylitis, Ankylosing / Q000276:immunology* / Q000628:therapy
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015796:HLA-B27 Antigen; D020381:Interleukin-17; D053759:Interleukin-23
keywords: Th17; ankylosing spondylitis; treatment